Paradigm Biopharmaceuticals Limited.. (PAR:ASX)

$1.82

right-arrow Created with Sketch. -0.105 (-5.45%)
MCAP $441.9M
Last trade 16.10pm 17/09/2021 20mins delayed

Latest Announcements

17/09/2021PARParadigm Biopharmaceuticals Limited..
1,871
MCap
17/09/2021PARParadigm Biopharmaceuticals Limited..
13/09/2021PARParadigm Biopharmaceuticals Limited..
27/08/2021PARParadigm Biopharmaceuticals Limited..
27/08/2021 Price SensitivePSPARParadigm Biopharmaceuticals Limited..
03/08/2021 Price SensitivePSPARParadigm Biopharmaceuticals Limited..
30/07/2021 Price SensitivePSPARParadigm Biopharmaceuticals Limited..
106,482
MCap
29/07/2021 Price SensitivePSPARParadigm Biopharmaceuticals Limited..

Company Overview

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The Company focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.

PAR in the news

Paradigm Biopharmaceuticals (PAR) tables revenue of more than $8.9 million for FY21…
The US FDA requests further clarification from Paradigm Biopharmaceuticals (PAR) for its…
Paradigm Biopharmaceuticals (PAR) submits its response to the US Food and Drug…
Paradigm Biopharmaceuticals (PAR) lands key regulatory approvals for a second-phase clinical trial…

Search Previous Announcements